Hadziselimovic F, Emmons L R, Gallati H
Department of Gastroenterology, Children's Hospital, Basle, Switzerland.
Gut. 1995 Aug;37(2):260-3. doi: 10.1136/gut.37.2.260.
The aim of the study was to discover if soluble tumour necrosis factor receptors (sTNF-R p55 and p75) in the urine of patients with inflammatory bowel disease (IBD) could be used to monitor the different stages of the activity of the diseases. Twenty five patients with either Crohn's disease or ulcerative colitis were followed up during a longterm study. The 16 patients who become acutely ill with either Crohn's disease or ulcerative colitis had significantly higher concentrations of sTNF-R p55 and p75 in their urine compared with those who were in remission, or those who were normal controls. There was a significant correlation between increased concentrations (> 20 ng/ml) of both sTNF-R p55 and p75 in the urine and a high Crohn's disease activity index (CDAI) and colitis activity index (CAI). Therefore, determination of sTNF-R is a good non-invasive parameter that can be used to assess the activity of disease and the efficacy of treatment.
该研究的目的是探究炎症性肠病（IBD）患者尿液中的可溶性肿瘤坏死因子受体（sTNF-R p55和p75）是否可用于监测疾病活动的不同阶段。在一项长期研究中，对25例克罗恩病或溃疡性结肠炎患者进行了随访。与处于缓解期的患者或正常对照组相比，16例患急性克罗恩病或溃疡性结肠炎的患者尿液中sTNF-R p55和p75的浓度显著更高。尿液中sTNF-R p55和p75浓度升高（>20 ng/ml）与高克罗恩病活动指数（CDAI）和结肠炎活动指数（CAI）之间存在显著相关性。因此，测定sTNF-R是一个良好的非侵入性参数，可用于评估疾病活动和治疗效果。
